Investigation of oral fenretinide for treatment of geographic atrophy in age-related macular degeneration

Retina

Volumn 33, Issue 3, 2013, Pages 498-507

  Mata, Nathan L ^a,b   Lichter, Jay B ^a   Vogel, Roger ^b   Han, Yun ^a,b   Bui, Tam V ^a,b   Singerman, Lawrence J ^c  

^a Re Vision Therapeutics Inc   (United States)

^b Sirion Therapeutics Inc   (United States)

^c Retina Associates of Cleveland   (United States)

Author keywords

age related macular degeneration; fenretinide; geographic atrophy; lipofuscin; N retinylidene N retinylethanolamine; retinal pigment epithelium; retinol binding protein; vitamin A

Indexed keywords

FENRETINIDE; PLACEBO; RETINOL; RETINOL BINDING PROTEIN;

ADULT; AGED; ARTICLE; BLURRED VISION; CATARACT; CONJUNCTIVITIS; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DRY EYE; EYE DISEASE; FEMALE; GASTROINTESTINAL DISEASE; GROWTH RATE; HEART DISEASE; HUMAN; INCIDENCE; LACRIMATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEOPLASM; NEUROLOGIC DISEASE; NIGHT BLINDNESS; PHASE 2 CLINICAL TRIAL; PROTEIN BLOOD LEVEL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA DEGENERATION; SIDE EFFECT; SKIN DISEASE; SUBCUTANEOUS FAT DISORDER; SUBRETINAL NEOVASCULARIZATION; VASCULAR DISEASE; VISUAL ACUITY; VISUAL DISORDER; VITAMIN BLOOD LEVEL;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CONTRAST SENSITIVITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FENRETINIDE; GEOGRAPHIC ATROPHY; HUMANS; MALE; MIDDLE AGED; QUESTIONNAIRES; RETINOL-BINDING PROTEINS, PLASMA; TREATMENT OUTCOME; VISUAL ACUITY; VITAMIN A;

EID: 84874950305     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e318265801d     Document Type: Article

References (48)

1. Dorey CK, Wu G, Ebenstein D, et al. Cell loss in the aging retina. Relationship to lipofuscin accumulation and macular degeneration. Invest Ophthalmol Vis Sci 1989;30:1691-1699
2. Zarbin MA. Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol 2004;122:598-614
3. Kanda A, Abecasis G, Swaroop A. Inflammation in the pathogenesis of age-related macular degeneration. Br J Ophthalmol 2008;92:448-450
4. Kennedy CJ, Rakoczy PE, Constable IJ. Lipofuscin of the retinal pigment epithelium: A review. Eye (Lond) 1995;9:763-771
5. Sparrow JR, Boulton M. RPE lipofuscin and its role in retinal pathobiology. Exp Eye Res 2005;80:595-606
6. Bergmann M, Schutt F, Holz FG, Kopitz J. Inhibition of the ATP-driven proton pump in RPE lysosomes by the major lipofuscin fluorophore A2E may contribute to the pathogenesis of age-related macular degeneration. FASEB J 2004;18:562-564
7. Sparrow JR, Zhou J, Ben-Shabat S, et al. Involvement of oxidative mechanisms in blue-light-induced damage to A2E-laden RPE. Invest Ophthalmol Vis Sci 2002;43:1222-1227
8. Lamb LE, Simon JD. A2E: A component of ocular lipofuscin. Photochem Photobiol 2004;79:127-136
9. Finnemann SC, Leung LW, Rodriguez-Boulan E. The lipofuscin component A2E selectively inhibits phagolysosomal degradation of photoreceptor phospholipid by the retinal pigment epithelium. Proc Natl Acad Sci U S A 2002;99:3842-3847
10. Bermann M, Schutt F, Holz FG, Kopitz J. Does A2E, a retinoid component of lipofuscin and inhibitor of lysosomal degradative functions, directly affect the activity of lysosomal hydrolases? Exp Eye Res 2001;72:191-195
11. Suter M, Remé C, Grimm C, et al. Age-related macular degeneration. The lipofusion component N-retinyl-N-retinylidene ethanolamine detaches proapoptotic proteins from mitochondria and induces apoptosis in mammalian retinal pigment epithelial cells. J Biol Chem 2000;275:39625-39630
12. Radu RA, Hu J, Yuan Q, et al. Complement system dysregulation and inflammation in the retinal pigment epithelium of a mouse model for Stargardt macular degeneration. J Biol Chem 2011;286:18593-18601
13. De S, Sakmar TP. Interaction of A2E with model membranes. Implications to the pathogenesis of age-related macular degeneration. J Gen Physiol 2002;120:147-157
14. Choudhry N, Giani A, Miller JW. Fundus autofluorescence in geographic atrophy: A review. Semin Ophthalmol 2010;25: 206-213. Review
15. Von Ruckmann A, Fitzke FW, Bird AC. In vivo autofluorescence in macular dystrophies. Arch Ophthalmol 1997;115:609-615
16. Holz FG, Bellman C, Staudt S, et al. Fundus autofluorescence and development of geographic atrophy in age-related macular degeneration. Invest Ophthalmol Vis Sci 2001;42:1051-1056
17. Schmitz-Valckenberg S, Bültmann S, Dreyhaupt J, et al. Fundus autofluorescence and fundus perimetry in the junctional zone of geographic atrophy in patients with age-related macular degeneration. Invest Ophthalmol Vis Sci 2004;45:4470-4476
18. Scholl HP, Bellmann C, Dandekar SS, et al. Photopic and scotopic fine matrix mapping of retinal areas of increased fundus autofluorescence in patients with age-related maculopathy. Invest Ophthalmol Vis Sci 2004;45:574-583
19. Owsley C, Jackson GR, White M, et al. Delays in rod-mediated dark adaptation in early age-related maculopathy. Ophthalmology 2001;108:1196-1202
20. Holz FG, Bindewald-Wittich A, Fleckenstein M, et al FAM-Study Group. Progression of geographic atrophy and impact of fundus autofluorescence patterns in age-related macular degeneration. Am J Ophthalmol 2007;143:463-472
21. Schmitz-Valckenberg S, Bindewald-Wittich A, Dolar-Szczasny J, et al Fundus Autofluorescence in Age-Related Macular Degeneration Study Group. Correlation between the area of increased autofluorescence surrounding geographic atrophy and disease progression in patients with AMD. Invest Ophthalmol Vis Sci 2006;47:2648-2654
22. Bindewald A, Schmitz-Valckenberg S, Jorzik JJ, et al. Classification of abnormal fundus autofluorescence patterns in the junctional zone of geographic atrophy in patients with age related macular degeneration. Br J Ophthalmol 2005;89:874-878
23. Kawaguchi R, Yu J, Honda J, et al. A membrane receptor for retinol binding protein mediates cellular uptake of vitamin A. Science 2007;315:820-825
24. Blaner WS. STRA6, a cell-surface receptor for retinol-binding protein: The plot thickens. Cell Metab 2007;5:164-166
25. Formelli F, Clerici M, Campa T, et al. Five-year administration of fenretinide: Pharmacokinetics and effects on plasma retinol concentrations. J Clin Oncol 1993;11:2036-2042
26. Conley B, O'Shaughnessy J, Prindiville S, et al. Pilot trial of the safety, tolerability, and retinoid levels of N-(4-hydroxyphenyl) retinamide in combination with tamoxifen in patients at high risk for developing invasive breast cancer. J Clin Oncol 2000; 18:275-283
27. Camerini T, Mariani L, De Palo G, et al. Safety of the synthetic retinoid fenretinide: Long-Term results from a controlled clinical trial for the prevention of contralateral breast cancer. J Clin Oncol 2001;19:1664-1670
28. Mariani L, Formelli F, De Palo G, et al. Chemoprevention of breast cancer with fenretinide (4-HPR): Study of long-Term visual and ophthalmologic tolerability. Tumori 1996;82:444-449
29. Veronesi U, Mariani L, Decensi A, et al. Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol 2006;17:1065-1071
30. Baglietto L, Torrisi R, Arena G, et al. Ocular effects of fenretinide, a vitamin A analog, in a chemoprevention trial of bladder cancer. Cancer Detect Prev 2000;24:369-375
31. Caruso RC, Zujewski J, Iwata F, et al. Effects of fenretinide (4-HPR) on dark adaptation. Arch Ophthalmol 1998;116: 759-763
32. Kaiser-Kupfer MI, Peck GL, Caruso RC, et al. Abnormal retinal function associated with fenretinide, a synthetic retinoid. Arch Ophthalmol 1986;104:69-70
33. Maeda A, Maeda T, Golczak M, et al. Effects of potent inhibitors of the retinoid cycle on visual function and photoreceptor protection from light damage in mice. Mol Pharmacol 2006;70: 1220-1229
34. Berni R, Formelli F. In vitro interaction of fenretinide with plasma retinol-binding protein and its functional consequences. FEBS Lett 1992;308:43-45
35. Malpeli G, Folli C, Berni R. Retinoid binding to retinol-binding protein and the interference with the interaction with transthyretin. Biochim Biophys Acta 1996;1294:48-54
36. Quadro L, Blaner WS, Hamberger L, et al. The role of extrahepatic retinol binding protein in the mobilization of retinoid stores. J Lipid Res 2004;45:1975-1982
37. Vogel S, Piantedosi R, O'Byrne SM, et al. Retinol-binding protein-deficient mice: Biochemical basis for impaired vision. Biochemistry 2002;41:15360-15368
38. Radu RA, Han Y, Bui TV, et al. Reductions in serum vitamin A arrest accumulation of toxic retinal fluorophores: A potential therapy for treatment of lipofuscin-based retinal diseases. Invest Ophthalmol Vis Sci 2005;46:4393-4401
39. Avalle LB,Wang Z, Dillon JP, Gaillard ER. Observation of A2E oxidation products in human retinal lipofuscin. Exp Eye Res 2004;78:895-898
40. Lewis KC, Zech LA, Phang JM. Effects of chronic administration of N-(4-hydroxyphenyl)retinamide (4-HPR) in rats on vitamin A metabolism in the eye. Eur J Cancer 1996;32A:1803-1808.
41. Taren DL, Duncan B, Shrestha K, et al. The night vision threshold test is a better predictor of low serum vitamin A concentration than self-reported night blindness in pregnant urban Nepalese women. J Nutr 2004;134:2573-2578
42. World Health Organization. Indicators for Assessing Vitamin A Deficiency and their Application in Monitoring and Evaluating Intervention Programmes. Eileen Brown, James Akré, eds. Geneva, Switzerland: World Health Organization, 1996. WHO/NUT/96.10
43. Lindblad AS, Lloyd PC, Clemons TE, et al. Change in area of geographic atrophy in the Age-Related Eye Disease Study: AREDS report number 26. Arch Ophthalmol 2009;127: 1168-1174
44. Sunness JS, Rubin GS, Applegate CA, et al. Visual function abnormalities and prognosis in eyes with age-related geographic atrophy of the macula and good visual acuity. Ophthalmology 1997;104:1677-1691
45. Sunness JS, Applegate CA, Gonzalez-Baron J. Improvement of visual acuity over time in patients with bilateral geographic atrophy from age-related macular degeneration. Retina 2000; 20:162-169
46. Sogno I, Venè R, Sapienza C, et al. Anti-Angiogenic properties of chemopreventive drugs: Fenretinide as a prototype. Recent Results Cancer Res 2009;181:71-76
47. Ribatti D, Raffaghello L, Marimpietri D, et al. Fenretinide as an anti-Angiogenic agent in neuroblastoma. Cancer Lett 2003; 197:181-184
48. Sunness JS, Gonzalez-Baron J, Bressler NM, et al. The development of choroidal neovascularization in eyes with the geographic atrophy form of age-related macular degeneration. Ophthalmology 1999;106:910-919